Published on

February 5, 2026

Last updated on

March 13, 2026

Medical Devices in China: A Regulatory Glossary for NMPA Compliance

Entering the market for medical devices in China rarely feels like a simple extension of a US FDA or EU MDR strategy. While familiar concepts such as classification, technical documentation, and post-market surveillance still apply, China approaches them through its own regulatory language, documents, and lifecycle rules under the National Medical Products Administration (NMPA).

This China medical device glossary is structured to reflect how regulators evaluate products, following the lifecycle path manufacturers are expected to navigate (click to scroll):

By presenting key terms within this lifecycle context, this medical device glossary for China helps teams avoid false equivalence with US or EU systems and align global stakeholders much earlier in the China planning process.

Continue below for the full glossary, or get in touch with Cisema for support with Chinese medical device registration and ongoing NMPA compliance management.

Chinese Regulatory Authorities Governing Medical Devices in China

China’s framework is centralized, and responsibilities are defined by law and implementing measures.

National Medical Products Administration (NMPA)

The NMPA is China’s central authority for medical device supervision and administration nationwide. It sets national regulatory expectations and oversees lifecycle regulation through registration rules, standards systems, and enforcement mechanisms.

More information is available on the official NMPA English website (English).

Center For Medical Device Evaluation (CMDE)

CMDE is the NMPA’s technical review body for key parts of the registration system, including technical evaluation of registration applications (notably imported devices and domestic Class III), as well as change and renewal technical evaluations under China’s registration and filing measures.

Additional details can be found on the CMDE official information page (English).

Regulations On Supervision and Administration of Medical Devices (State Council Order No. 739)

State Council Order No. 739 is China’s top-level medical device regulation and has been implemented since June 1, 2021. It applies across the full device lifecycle (R&D through supervision) and is supported by implementing measures and guidance.

With the legal foundation established, companies can next determine whether their product falls under China’s device definition and how it should be classified.

Medical Device Definition and Classification Under Chinese Regulation

China’s definition is broad, but the practical application is precise. Classification and product code selection drive nearly every downstream requirement.

Medical Device (China Legal Definition)

In China, a medical device includes instruments, equipment, in vitro diagnostic reagents (and related items), materials, and software intended for human use where the primary intended effect is achieved mainly through physical means rather than pharmacological, immunological, or metabolic action (even if those effects are present only as auxiliary).

Medical Device Classification in China (Class I, II, III)

China uses a 3-class risk system:

Class I: Low risk, generally managed through filing/record-filing
Class II: Moderate risk, requires registration review
Class III: High risk, requires stricter registration controls and review depth

Classification impacts dossier depth, type testing expectations, and post-market duties.

For a deeper understanding of how classification works in practice, consult our detailed guides to China medical device risk classification and China IVD device risk classification.

Product Code in China

The product code is the catalog-based identifier used to place a device into a defined category, linking it to class and often to expected standards and technical review logic. In practice, product code selection is one of the earliest “lock-in” decisions for an NMPA strategy because it shapes testing and documentation expectations.

With classification set, China’s next question is not “who sells it,” but “who is accountable for it.”

Registration Roles and Market Access Responsibilities for Medical Devices in China

China’s system emphasizes a single accountable party for lifecycle compliance, supported by a local representative function for overseas manufacturers.

Medical Device Registrant / Record Holder in China

China assigns lifecycle responsibility to the applicant/filing entity (often described in practice as registrant for Class II/III and record holder for Class I). This responsible entity bears obligations across design, manufacturing control, vigilance, and post-market compliance under the updated framework.

NMPA Legal Agent (Local Authorized Representative or Chinese Agent)

For overseas manufacturers, a China-established entity commonly serves as the local interface for submissions and lifecycle obligations in-market (e.g., communications, reporting workflows, and administrative execution). While roles are often compared to US Agent / EU Authorized Representative, the operational workload in China is typically broader because multiple ongoing submissions flow through local channels.

The NMPA Legal Agent role is proposed to be renamed to the Domestic Responsible Agent (“DRA”) and responsibilities further increased under the new draft Medical Device Law.

Chinese Medical Device Registration Certificate

The NMPA issues a medical device registration certificate upon approval for registered devices, and the standard validity period is generally 5 years. Renewal must be planned before expiry and generally submitted at least 6 months prior. However, we usually recommend our clients to start 2 years before expiry in case standard changes necessitate new type testing or other major changes.

Technical Documentation and Type Testing for Medical Devices in China

Among the most common source of confusion for global teams is China’s unique technical documentation set — especially the product technical requirements (“PTR”) and mandatory type testing. China’s pre-market evidence is strongly anchored in localized documents and China-specific testing routes.

Product Technical Requirements (PTR)

The PTR is a required regulatory document prepared by the applicant/filing entity. Under China’s registration and filing provisions, PTR content focuses on functional and safety indicators and test methods that can be objectively determined for the finished device, and products must comply with the PTR as registered/filed.

Practical clarification for global teams: the PTR is not simply a “spec sheet.” In China it functions as a compliance anchor that supports testing, review, and later change/renewal activities.

Type Testing in China (In-Country Testing)

Type testing typically refers to testing performed by designated Chinese laboratories against applicable Chinese standards and the approved PTR framework. This is a distinctive feature of NMPA pathways and is often required even when robust overseas test data exists, because China expects evidence to map to China’s standards environment and review conventions.

Clinical Evaluation for Medical Devices in China

Clinical evaluation is the structured assessment of clinical evidence supporting safety and performance, which may involve clinical trials, literature, or comparison-based justification depending on product and pathway. CMDE is explicitly responsible for technical evaluation of registration applications and also handles clinical trial approval applications where required.

China Clinical Trial Exemption List

China uses exemption mechanisms for certain device categories, typically through published catalogs/lists and related guidance that define when clinical trials may be exempted, subject to eligibility conditions and evidence expectations.

Because these terms can look familiar on the surface, it helps to anchor them against US and EU language without assuming they are identical.

Labeling and Intended Use Requirements for Medical Devices in China

In China, labeling and intended use consistency are treated as compliance controls. Misalignment between IFU, claims, PTR, and registration scope commonly triggers review questions.

Intended Use in China

The intended use statement anchors classification logic, evidence expectations, and labeling scope. Shifts in intended use often cascade into change requirements because they can alter risk profile, clinical claims, and applicable standards.

Chinese Labeling and Instructions for Use (IFU)

China’s registration and filing provisions require applicants/filing entities to prepare IFU and labels, and these must conform to requirements in the device regulations and supporting provisions.

Once a device is approved, regulatory responsibility does not diminish. It shifts into ongoing surveillance, structured reporting, and controlled change.

Post-Market Surveillance and Lifecycle Compliance for Medical Devices in China

China’s post-market framework is active and recurring, with defined expectations for reporting and risk evaluation.

Post-Market Surveillance (PMS) In China

PMS includes systematic monitoring of device performance and safety in the field, using complaints, adverse events, trend review, and corrective action mechanisms. PMS outputs often feed into PRER and annual reporting.

Periodic Risk Evaluation Report (PRER)

NMPA issued a writing specification for PRERs to guide consistent preparation of periodic risk evaluation reports for medical devices. This concept is frequently compared to the EU PSUR, but China’s structure and submission expectations are defined by its own guidance.

Annual Self-Inspection Report

Overseas manufacturers commonly manage annual reporting through their China-side representation mechanisms, covering defined compliance topics such as changes, vigilance, and quality-related outcomes.

Change Registration in China

China distinguishes between administrative changes and changes that may affect safety/performance or registered content, with formal “change registration” pathways under the registration and filing system. CMDE’s responsibilities explicitly include technical evaluation of change registration applications for certain categories.

China NMPA Vs US FDA Vs EU MDR Regulatory Terminology for Medical Devices:

The table below summarizes commonly compared regulatory concepts and their rough equivalents across China, the US, and the EU.

FeatureNMPA (China)FDA (USA) EU MDR (Europe) Primary Legislation Order 739 (Decree 739) FD&C Act (21 CFR 820/807) Regulation (EU) 2017/745 Regulatory Authority NMPA US Food and Drug Administration (FDA) Notified Bodies and Competent Authorities Risk Classification Class I, II, III (Similar to FDA) Class I, II, III (Risk-based) Class I, IIa, IIb, III Pre-market Pathway Registration/Approval 510(k), De Novo, PMA (as applicable) CE Marking (via Notified Body) Local Representative NMPA Legal Agent US Agent Authorized Representative Submission Language Chinese language only English English and/or local EU language(s), depending on Notified Body and Member State

Navigating Medical Device Regulation in China with Confidence

This glossary brings together the key terms that shape how medical device regulation in China actually works in practice. When classification, technical documentation, testing, labeling, and post-market duties are understood as one connected system, regulatory expectations become far clearer and easier to manage.

With more than 20 years of experience supporting international manufacturers in China, Cisema helps companies handle NMPA registration and lifecycle compliance as a single, coordinated process. For support in reducing regulatory friction, accelerating approvals, and maintaining long-term compliance in the Chinese medical device market, get in touch with Cisema today.

Further Information

To support your medical device market entry and regulatory planning across Asia, explore Cisema’s dedicated medical device compliance services by region: